HAS3 and ovarian serous adenocarcinoma: We found that HAS2 (Figure 2b) and HAS3 (Figure 2c) but not HAS1 (Figure 2a) expression is significantly increased in primary serous ovarian cancer cells isolated from the ascites of patients with chemoresistant disease compared to patients with chemosensitive disease.